Literature DB >> 28133975

Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Manli Jiang1, N Nora Bennani2, Andrew L Feldman1.   

Abstract

INTRODUCTION: Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional depth to this complexity. Areas covered: Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. The present review focuses on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic and dendritic cell neoplasms, summarizing changes reflected in the 2016 revision to the WHO classification. These changes are critical to hematologists and other clinicians who care for patients with these disorders. Expert commentary: Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revisions in the WHO classification particularly impact T-cell lymphomas, including a new umbrella category of T-follicular helper cell-derived lymphomas and evolving recognition of indolent T-cell lymphomas and lymphoproliferative disorders.

Entities:  

Keywords:  Hodgkin lymphoma; Non-Hodgkin lymphoma; T-cell lymphoproliferative disorder; World Health Organization (WHO); anaplastic large cell lymphoma; angioimmunoblastic T-cell lymphoma; dendritic cell tumors; histiocytic sarcoma; lymphoma classification; peripheral T-cell lymphoma

Mesh:

Year:  2017        PMID: 28133975      PMCID: PMC5514564          DOI: 10.1080/17474086.2017.1281122

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  110 in total

Review 1.  Angioimmunoblastic T-cell lymphoma.

Authors:  Ahmet Dogan; Ayoma D Attygalle; Chara Kyriakou
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

2.  Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans' cell sarcoma: evidence for hematopoietic plasticity.

Authors:  Richard Ratei; Michael Hummel; Ioannis Anagnostopoulos; Doris Jähne; Renate Arnold; Bernd Dörken; Stephan Mathas; Thomas Benter; Oliver Dudeck; Wolf-Dieter Ludwig; Harald Stein
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

3.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

4.  Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?

Authors:  Tony Petrella; Eve Maubec; Pascale Cornillet-Lefebvre; Rein Willemze; Michel Pluot; Anne Durlach; Eduardo Marinho; Jean-Luc Benhamou; Patty Jansen; Alistair Robson; Florent Grange
Journal:  Am J Surg Pathol       Date:  2007-12       Impact factor: 6.394

5.  Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.

Authors:  Sylvia Hartmann; Claudia Döring; Emily Vucic; Fong Chun Chan; Daisuke Ennishi; Thomas Tousseyn; Christiane de Wolf-Peeters; Sven Perner; Iwona Wlodarska; Christian Steidl; Randy D Gascoyne; Martin-Leo Hansmann
Journal:  Br J Haematol       Date:  2015-02-02       Impact factor: 6.998

Review 6.  Systemic lymphoma arising from hydroa vacciniforme-like lymphoma: report of two cases with review of literature.

Authors:  Yu-Qiong Yang; Lei Fan; Li Wang; Ji Xu; Run Zhang; Zheng Ge; Jian-Yong Li; Wei Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

7.  Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study.

Authors:  Evaldas Laurencikas; Désirée Gavhed; Helen Stålemark; Ingrid van't Hooft; Daniela Prayer; Nicole Grois; Jan-Inge Henter
Journal:  Pediatr Blood Cancer       Date:  2011-02       Impact factor: 3.167

8.  Diffuse lymphocyte-predominant Hodgkin's disease (diffuse paragranuloma). A variant of the B-cell-derived nodular type.

Authors:  M L Hansmann; H Stein; F Dallenbach; C Fellbaum
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

9.  Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Ranjana H Advani; Sandra J Horning; Richard T Hoppe; Sarah Daadi; John Allen; Yasodha Natkunam; Nancy L Bartlett
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

10.  DUSPs, to MAP kinases and beyond.

Authors:  Ching-Yu Huang; Tse-Hua Tan
Journal:  Cell Biosci       Date:  2012-07-09       Impact factor: 7.133

View more
  34 in total

Review 1.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

2.  Curcumin in Combination With Omacetaxine Suppress Lymphoma Cell Growth, Migration, Invasion, and Angiogenesis via Inhibition of VEGF/Akt Signaling Pathway.

Authors:  Yu Zhang; Jingjing Xiang; Ni Zhu; Hangping Ge; Xianfu Sheng; Shu Deng; Junfa Chen; Lihong Yu; Yan Zhou; Jianping Shen
Journal:  Front Oncol       Date:  2021-08-11       Impact factor: 6.244

3.  Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy.

Authors:  Chenjiao Yao; Ruoyao Xu; Qianyuan Li; Sheng Xiao; Min Hu; Linyong Xu; Quan Zhuang
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

4.  The Risk of Developing Lymphoma among Autoimmune Thyroid Disorder Patients: A Cross-Section Study.

Authors:  Mubarak Al-Mansour; Alaa Fawzi Maglan; Meral Khalid Altayeb; Laila Ali Faraj; Esraa Aman Felimban; Syed Sameer Aga; Mohammad Anwar Khan
Journal:  Dis Markers       Date:  2022-06-03       Impact factor: 3.464

5.  Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.

Authors:  Qing Wen; Jingjing Ge; Yaxin Lei; Yue Zhang; Xiaoshuang Kong; Wenhua Wang; Huting Hou; Zeyuan Wang; Siyu Qian; Mengjie Ding; Meng Dong; Linan Zhu; Mingzhi Zhang; Xudong Zhang; Qingjiang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-28       Impact factor: 4.322

Review 6.  Tip of the iceberg: roles of circRNAs in hematological malignancies.

Authors:  Shan-Shan Guo; Bi-Xia Li; Duo-Bing Zou; Shu-Jun Yang; Li-Xia Sheng; Gui-Fang Ouyang; Qi-Tian Mu; He Huang
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

7.  Targeting epigenetic regulators in the treatment of T-cell lymphoma.

Authors:  Nada Ahmed; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2020-01-22       Impact factor: 2.929

8.  KIF15 is involved in development and progression of Burkitt lymphoma.

Authors:  Zhao Wang; Meiting Chen; Xiaojie Fang; Huangming Hong; Yuyi Yao; He Huang
Journal:  Cancer Cell Int       Date:  2021-05-13       Impact factor: 5.722

Review 9.  Transient Receptor Potential (TRP) Channels in Haematological Malignancies: An Update.

Authors:  Federica Maggi; Maria Beatrice Morelli; Massimo Nabissi; Oliviero Marinelli; Laura Zeppa; Cristina Aguzzi; Giorgio Santoni; Consuelo Amantini
Journal:  Biomolecules       Date:  2021-05-20

10.  Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.

Authors:  Mehdi Hamadani; Graham P Collins; Paolo F Caimi; Felipe Samaniego; Alexander Spira; Andrew Davies; John Radford; Tobias Menne; Anand Karnad; Jasmine M Zain; Paul Fields; Karin Havenith; Hans G Cruz; Shui He; Joseph Boni; Jay Feingold; Jens Wuerthner; Steven Horwitz
Journal:  Lancet Haematol       Date:  2021-06       Impact factor: 30.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.